Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$55.7B
234M shares
52-week range
$137.75 – $240.93
98% from low
Sector
WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $136.81B | $145.53B | $152.92B | $162.47B | $181.33B | $204.98B | $226.83B | $222.58B |
| Cost of revenue | $129.63B | $138.70B | $146.05B | $155.69B | $174.84B | $198.10B | $219.41B | $214.41B |
| Gross profit | $7.18B | $6.83B | $6.87B | $6.78B | $6.48B | $6.89B | $7.41B | $8.17B |
| Gross margin | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $126.0M | $2.06B | −$4.10B | $472.0M | −$607.0M | $752.0M | $1.24B | $2.27B |
| EBITDA | $1.13B | $3.04B | −$2.62B | $1.29B | $55.0M | $1.44B | $1.96B | $3.11B |
| Net income | $256.0M | $1.36B | −$3.69B | $611.0M | −$938.0M | $330.0M | $852.0M | $1.56B |
| Net margin | 0.2% | 0.9% | -2.4% | 0.4% | -0.5% | 0.2% | 0.4% | 0.7% |
| EPS (diluted) | 0.81 | 4.53 | -12.60 | 2.08 | -3.34 | 1.26 | 3.45 | 6.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $256.1B | $10.77 | $10.72–$10.80 | 10 |
| 2027 | $277.1B | $12.01 | $11.70–$12.19 | 10 |
| 2028 | $299.2B | $13.52 | $10.19–$15.79 | 5 |
| 2029 | $322.7B | $15.02 | $14.43–$15.47 | 1 |
Forward consensus · source: Financial Modeling Prep
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
www.cardinalhealth.comNo one on the platform currently holds CAH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 344,825 | $72.9M |
| Bridgewater Associatesas of 2026-03-31 | 115,229 | $24.3M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-01 | $0.5158 | 2026-07-15 |
| 2026-04-01 | $0.5107 | 2026-04-15 |
| 2026-01-02 | $0.5107 | 2026-01-15 |
| 2025-10-01 | $0.5107 | 2025-10-15 |
| 2025-07-01 | $0.5107 | 2025-07-15 |
| 2025-04-01 | $0.5056 | 2025-04-15 |
| 2025-01-02 | $0.5056 | 2025-01-15 |
| 2024-10-01 | $0.5056 | 2024-10-15 |
| 2024-07-01 | $0.5056 | 2024-07-15 |
| 2024-03-28 | $0.5006 | 2024-04-15 |
No one on the platform has traded CAH yet.
| $9.0B |
| — |
| CORCencora, Inc. | $279.35 | -0.82% | $54.3B | — |
| EWEdwards Lifesciences Corporation | $89.93 | -1.37% | $51.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-29 |
| $0.5006 |
| 2024-01-15 |
| 2023-10-02 | $0.5006 | 2023-10-15 |
Trading at 37.2× earnings vs its 28.0× historical median P/E.
Fair value ≈ $179.72 · price $238.65 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@howardlindzon $CAH has been on a good run after some nice dip buying. 😁
View on StockTwits ↗$CAH Current Stock Price: $234.77 Contracts to trade: $235.0 CAH Jun 26 2026 Call Entry: $1.00 Exit: $1.31 ROI: 31% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$CAH cut my position in half. Holding with an average of ~202, planning to stick around. Happy to add if it dips back down.
View on StockTwits ↗@cynicaloptimist @Jblack500 @BustaCapital @MaverikIT @IsabellaDC $CAH just a great long term chart, hit another ath today
View on StockTwits ↗$CAH Slow but steady-moving stock. Been in it since 2022 and am up 370%. Pays a nice dividend of $0.518, too. Reliable. Currently at a 52-week high. The company made a structural transition from a low-margin drug distributor into a high-margin specialty medicine platform. $CAH is tracking to exceed $50 billion in specialty revenues for fiscal year 2026.
View on StockTwits ↗$CAH Share Price: $228.91 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $3.82 – $4.73 Target Zone: $6.46 – $7.90 Potential Upside: 60% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$CAH can you fucking move more 2-3% at a time??? Please and thank you
View on StockTwits ↗This man shares my style of investing. He chooses good names -- he also can smell the incoming volitility and choose lower beta names to ride out the wave. I used to make such posts but most people on st are only interested in instant 100% gains a day or they believe in the bum furu with thousands of lemmings following them. Follow @WuTangClam -- he is a real one. he did leave off some other names like $CVS $CAH $UNH that the algos positioned themselves for awhile to go hide out -- especially since the pullbacks. Good luck to anyone that bothers to use their brain today.
View on StockTwits ↗$CAH This and McKesson - flight to safety on RED days = ✍️
View on StockTwits ↗$CAH Reverse Head & Shoulder with good volume.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.